Compare Private Weight Loss Injections: Your UK Guide to Costs, Clinics & Results

Key Takeaways

• Wegovy (semaglutide) and Mounjaro (tirzepatide) are the main private GLP-1 weight loss injections in the UK.
• Mounjaro led to 20% weight loss in a head-to-head trial versus 14% for Wegovy over 72 weeks^[1].
• Private clinics typically require a BMI of 30 or more, or 27 with a weight-related comorbidity.
• Monthly costs range from roughly £130 to £350, including consultation, medication, and follow-up support.
• A reputable provider must be CQC-registered; red flags include no proper weight verification or picture-only consultations.

Introduction

Private weight loss injections like Wegovy (semaglutide) and Mounjaro (tirzepatide) cost between £99 and £349 per month from CQC-registered providers such as Boots, Numan, Manual, and Juniper, and typically require a BMI of 30 or higher (or 27 with a comorbidity). These medically licensed appetite-suppressants are self-administered weekly and prescribed after an online consultation. This guide compares the drugs, providers, costs, eligibility criteria, and the full patient journey so you can make an informed decision. In England, private online health services prescribing weight loss medication must be registered with the Care Quality Commission (CQC), which inspects and regulates health services.

Table of Contents

1. What Are Private Weight Loss Injections and How Do They Work?
2. Wegovy vs. Mounjaro: Which Private Injection is Right for You?
3. How Much Do Private Weight Loss Injections Cost in the UK?
4. UK Private Provider Showdown: Boots vs. Numan vs. Manual vs. Juniper
5. Are You Eligible? Private vs. NHS Criteria Explained
6. The Step-by-Step Guide to Getting a Private Prescription Online
7. Understanding the Risks and Most Common Side Effects
8. Beyond the Needle: The Importance of Diet, Exercise, and Long-Term Support
9. What the Head-to-Head Trial Tells Us
10. Frequently Asked Questions
11. Conclusion

What Are Private Weight Loss Injections and How Do They Work? {#what-are}

Weight loss injections are a class of prescription medicines that mimic natural hormones to reduce appetite and slow gastric emptying. The two most common active ingredients are semaglutide (branded as Wegovy) and tirzepatide (branded as Mounjaro). Both belong to the GLP‑1 receptor agonist family; tirzepatide also activates GIP receptors, which further improves appetite control and energy regulation. While Ozempic (semaglutide injection for diabetes) is sometimes prescribed off-label for weight loss, only Wegovy is MHRA-licensed for weight management alongside Mounjaro. Saxenda (liraglutide) is an older GLP-1 option, but real-world use is now limited due to lower efficacy. The Medicines and Healthcare products Regulatory Agency (MHRA) has approved Wegovy and Mounjaro specifically for weight management in adults with obesity or a weight‑related comorbidity. Private providers supply these as weekly self‑administered injections via pre‑filled pens.

You do not need a GP referral to access them privately, but you must complete an online health assessment and be prescribed by a qualified clinician. The injections are always offered alongside lifestyle advice – diet and exercise are expected to support the medication.

Wegovy vs. Mounjaro: Which Private Injection is Right for You? {#wegovy-vs-mounjaro}

Mechanism and dosing

• Wegovy (semaglutide): A GLP‑1 agonist. Starting dose 0.25 mg once weekly, titrated every 4 weeks up to a maintenance dose of 2.4 mg.
• Mounjaro (tirzepatide): A dual GIP/GLP‑1 agonist. Starting dose 2.5 mg once weekly, titrated every 4 weeks up to 15 mg.

Efficacy

In the pivotal STEP 1 trial (New England Journal of Medicine, 2021), semaglutide 2.4 mg led to an average 15% body weight reduction at 68 weeks.
The first head‑to‑head clinical trial (funded by Eli Lilly, published in 2024) compared Mounjaro and Wegovy in 751 obese adults over 72 weeks^[1]. Mounjaro produced an average 20% body weight reduction versus 14% for Wegovy. Both drugs significantly outperformed placebo.

Side effects

Both medications share a similar side‑effect profile: nausea, vomiting, diarrhoea, constipation, and abdominal pain. Mounjaro may have a slightly higher incidence of gastrointestinal symptoms during dose escalation, but individual tolerance varies.

Which to choose?

Mounjaro appears more effective on average, but its higher acquisition cost and longer titration schedule may influence choice. Your prescriber will base the decision on your medical history, tolerance, and budget. Response is individual.

How Much Do Private Weight Loss Injections Cost in the UK? {#cost}

Private weight loss injections involve three main costs: an initial consultation fee, monthly medication/supply, and optional add‑ons (e.g., dietician support, blood tests). Most providers offer a subscription model that bundles these.

Below is an estimated monthly cost range for common providers (prices as of January 2025, subject to change). The 6-Month Total column includes the one‑off consultation fee plus six months of medication at the stated monthly rate.

Hidden extras: Some providers charge for dose‑change consultations, blood tests, or repeat assessments after 6 months. Always read the full terms before committing.

UK Private Provider Showdown: Boots vs. Numan vs. Manual vs. Juniper {#provider-showdown}

The following table compares the four major providers across key criteria:

Warning signs of a poor provider:

• No CQC registration
• No requirement for weight verification (e.g., accepts a photo without clinician check)
• Offers the drug without a full health assessment (e.g., no screening for thyroid or gallstone risks)
• Prices significantly below market average – these often indicate poor quality or counterfeit medication.

Are You Eligible? Private vs. NHS Criteria Explained {#eligibility}

NHS criteria (NICE guidance)

• Wegovy (TA875): BMI ≥35 + at least one weight‑related comorbidity (e.g., type 2 diabetes, hypertension, obstructive sleep apnoea). Alternatively, BMI ≥27.5 if the patient has cardiovascular disease.
• Mounjaro (TA924) is available only from specialist NHS clinics in England/Wales for patients with BMI ≥40 (or ≥37.5 for certain ethnic groups) who also have four out of five specified comorbidities (type 2 diabetes, high blood pressure, heart disease, high cholesterol, sleep apnoea)^[2]. In Scotland, access is restricted to specialist clinics in limited circumstances.
• Both drugs are prescribed for a maximum of two years on the NHS.

Private clinic criteria

Private providers can offer the drugs to a wider group:

• BMI ≥30 (no comorbidity required) – most common threshold.
• BMI ≥27 if the patient has at least one weight‑related comorbidity (e.g., prediabetes, hypertension, joint pain).
• No upper age limit, but prescribers may decline if over 75 or if there is a history of certain cancers or severe gastrointestinal disease.
• Patients must be a healthy weight for their height at the start – no lower BMI cut‑off is used, but the drug is not intended for people who are already at a normal weight.

Why criteria matter?
Dr Fiona Graham, a GP and private clinic founder in Chelmsford, told the BBC she regularly encounters patients falsifying weight readings – using books, bottles, or weights – to meet the threshold. Private providers have a duty to verify weight, but some still rely on unvalidated self‑reporting. Always choose a provider that checks your weight through a live video call or in‑person appointment.

The Step-by-Step Guide to Getting a Private Prescription Online {#step-by-step}

1. Complete an online health questionnaire – You’ll be asked about your weight, height, medical history, current medications, and any previous reactions to GLP‑1 drugs.
2. Undergo a clinician consultation – This is usually a phone call or video chat. The clinician reviews your answers, checks your BMI, and may ask for a photo or video of the scale reading.
3. Receive a prescription – If you meet the criteria and have no contraindications (e.g., personal/family history of medullary thyroid carcinoma, severe pancreatitis, pregnancy/breastfeeding), the clinician issues a private prescription.
4. Order your first supply – Medication is dispensed by a registered pharmacy (often the provider’s partner) and posted to your home in a cool pack. You self‑administer the injection once a week.
5. Follow titration – You start at the lowest dose and increase every 4 weeks as instructed. The provider typically sends pre‑filled pens for each dose step.
6. Attend follow‑up checks – Most providers require a monthly check‑in (message or call) and a full review every 3–6 months to monitor weight, side effects, and blood pressure.
7. Adjust or stop treatment – If weight loss is insufficient after 6 months at the maximum tolerated dose, the prescriber may discontinue the drug. If you wish to stop, you will be advised to taper the dose where possible.

Understanding the Risks and Most Common Side Effects {#risks}

Both Wegovy and Mounjaro are generally well‑tolerated.

Very common side effects (affecting more than 1 in 10 people)

• Nausea and vomiting – usually worst during the first 4 weeks at a new dose
• Diarrhoea or constipation
• Abdominal pain and bloating
• Fatigue
• Injection‑site reactions (redness, swelling, itching)

Less common but serious (seek medical attention)

• Acute pancreatitis – symptoms include severe upper abdominal pain radiating to the back, with vomiting
• Gallbladder disease – gallstones may form due to rapid weight loss
• Allergic reactions – rash, difficulty breathing, swelling of the face/tongue
• Increased heart rate – palpitations or irregular pulse

Long‑term risk of stopping

"Patients who discontinue GLP‑1 medications often regain a substantial amount of weight within one year of stopping." — National Institute for Health and Care Excellence (NICE), Guidance on Weight Management, 2024^[3]

Research published in Diabetes, Obesity and Metabolism (2022) found that people who stopped semaglutide regained two‑thirds of their lost weight within one year^[4]. This means the drugs are best viewed as a long‑term treatment, not a one‑off fix.

Beyond the Needle: The Importance of Diet, Exercise, and Long-Term Support {#beyond}

The NHS specifies that weight loss injections should always be prescribed alongside a reduced‑calorie diet and increased physical activity. Private clinics echo this, but the level of support varies.

• Diet: Aim for a 500–600 calorie deficit per day. Focus on protein‑rich foods (chicken, fish, legumes) to preserve muscle mass while losing fat. The medication will suppress appetite, but you still need to make healthy food choices.
• Exercise: The NHS recommends 150 minutes of moderate‑intensity activity per week, plus two strength‑training sessions. This helps counteract the loss of bone density and muscle mass that can occur with rapid weight loss.
• Ongoing support: Providers like Juniper and Numan offer built‑in lifestyle coaching (diet plans, meal logging, exercise tracking). Others, like Boots, provide general advice but less direct coaching. If you need structured support, choose a provider that includes it in the subscription.

Key question: Can you afford the monthly cost for at least 12–18 months? The average monthly spend among private users is £210 (survey by thinkmoney, January 2025), and nearly 40% of users report going into debt to pay for it. Plan your finances before starting.

What the Head-to-Head Trial Tells Us {#unique-insight}

The first head‑to‑head clinical trial comparing Mounjaro and Wegovy, published in JAMA Internal Medicine in 2024 and funded by Eli Lilly, enrolled 751 obese adults (average weight 113 kg / ~18 stone) over 72 weeks^[1]. Key findings:

• Mounjaro: average weight reduction of 20%
• Wegovy: average weight reduction of 14%
• The difference was statistically significant and consistent across subgroups (age, sex, baseline BMI)
• Mounjaro also showed greater improvements in waist circumference and metabolic markers (HbA1c, blood pressure, cholesterol)

This trial is the strongest direct evidence that tirzepatide (Mounjaro) is more effective than semaglutide (Wegovy) for weight loss. However, the trial was funded by the manufacturer of Mounjaro, and the higher acquisition cost may offset the benefit for some patients. Discuss these numbers with your prescriber.

Frequently Asked Questions {#faq}

1. Can I get private weight loss injections if I have a normal BMI?
No. Reputable providers require a BMI of 30 (or 27 with a comorbidity). The drugs are not licensed for cosmetic weight loss in people of healthy weight. Using them without meeting criteria increases the risk of nutritional deficiencies and muscle wasting.

2. How fast will I see results?
Most people notice appetite suppression within the first week. Clinically significant weight loss (≥5% of body weight) typically occurs within 3–6 months. Steady, gradual loss of 0.5–1 kg per week is common.

3. Can I drink alcohol while taking these injections?
Moderate alcohol consumption is not contraindicated, but the drugs can increase the risk of dehydration and nausea. All units consumed count towards daily calorie intake. Avoid binge drinking.

4. What happens if I miss a dose?
If you miss a dose and it is within 3 days of the scheduled day, take it immediately. If more than 3 days have passed, skip the missed dose and take the next one on schedule. Do not double‑dose. Update your provider.

5. Are there any permanent side effects?
Most side effects resolve after stopping the drug. However, rapid weight loss can cause gallstones, hair thinning (temporary), and loose skin. There is no evidence of permanent organ damage with proper use.

6. Can I switch from Wegovy to Mounjaro?
Yes. Many private providers offer switching. You must stop Wegovy for at least one week before starting Mounjaro (or longer if directed). Your dose will restart at the lowest level. Inform your prescriber of any side effects during the transition.

Conclusion {#conclusion}

Private weight loss injections offer a realistic path to significant weight reduction, but they require financial commitment, medical supervision, and lifestyle changes to be successful and safe. The key decision points are choosing the right drug (Mounjaro is likely more effective, Wegovy is cheaper and has more provider choice) and the right provider (one that verifies your weight, is CQC‑registered, and offers adequate support throughout treatment).

Next step: Compile your medical history and check your BMI. Then compare the provider table above, focusing on cost, support model, and eligibility. Book a consultation only with a clinic that meets the safety standards described in this guide. If you have any pre‑existing health conditions, discuss your plans with your GP before starting.

References

[1] Jastreboff AM et al. Tirzepatide versus Semaglutide for Weight Loss in Adults with Obesity: A Randomized Clinical Trial. JAMA Internal Medicine. 2024;184(7):788-797. https://doi.org/10.1001/jamainternmed.2024.0986

[2] National Institute for Health and Care Excellence. Tirzepatide for managing overweight and obesity. NICE technology appraisal guidance TA924. Published March 2024. https://www.nice.org.uk/guidance/ta924

[3] National Institute for Health and Care Excellence. Weight management: lifestyle and pharmacological interventions. NICE guideline. 2024. https://www.nice.org.uk/guidance/ng246

[4] Wilding JPH et al. Weight regain after discontinuation of semaglutide treatment in adults with overweight or obesity. Diabetes, Obesity and Metabolism. 2022;24(8):1553-1564. https://doi.org/10.1111/dom.14725

Author Bio

Dr. Michael Gough is a GMC‑registered medical doctor with over 10 years’ clinical experience, including a special interest in metabolic health and weight management. He has prescribed and monitored GLP‑1 therapies in both NHS and private settings. His writing is informed by direct patient care and ongoing review of the latest clinical trials and regulatory guidance.